138 related articles for article (PubMed ID: 6433222)
1. Use of phenelzine in continuation therapy.
Davidson J; Raft D
Neuropsychobiology; 1984; 11(3):191-4. PubMed ID: 6433222
[TBL] [Abstract][Full Text] [Related]
2. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study.
Robinson DS; Lerfald SC; Bennett B; Laux D; Devereaux E; Kayser A; Corcella J; Albright D
Psychopharmacol Bull; 1991; 27(1):31-9. PubMed ID: 1862204
[TBL] [Abstract][Full Text] [Related]
3. Phenelzine for chronic depression: a study of continuation treatment.
Harrison W; Rabkin J; Stewart JW; McGrath PJ; Tricamo E; Quitkin F
J Clin Psychiatry; 1986 Jul; 47(7):346-9. PubMed ID: 3522558
[TBL] [Abstract][Full Text] [Related]
4. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.
Cornelius JR; Soloff PH; Perel JM; Ulrich RF
Am J Psychiatry; 1993 Dec; 150(12):1843-8. PubMed ID: 8238640
[TBL] [Abstract][Full Text] [Related]
5. Relapse of depressed patients after effective continuation therapy.
Georgotas A; McCue RE
J Affect Disord; 1989; 17(2):159-64. PubMed ID: 2527891
[TBL] [Abstract][Full Text] [Related]
6. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design.
Quitkin FM; Harrison W; Stewart JW; McGrath PJ; Tricamo E; Ocepek-Welikson K; Rabkin JG; Wager SG; Nunes E; Klein DF
Arch Gen Psychiatry; 1991 Apr; 48(4):319-23. PubMed ID: 2009033
[TBL] [Abstract][Full Text] [Related]
7. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.
Jarrett RB; Schaffer M; McIntire D; Witt-Browder A; Kraft D; Risser RC
Arch Gen Psychiatry; 1999 May; 56(5):431-7. PubMed ID: 10232298
[TBL] [Abstract][Full Text] [Related]
8. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients.
Georgotas A; McCue RE; Cooper TB
Arch Gen Psychiatry; 1989 Sep; 46(9):783-6. PubMed ID: 2673129
[TBL] [Abstract][Full Text] [Related]
9. How effective and safe is continuation therapy in elderly depressed patients? Factors affecting relapse rate.
Georgotas A; McCue RE; Cooper TB; Nagachandran N; Chang I
Arch Gen Psychiatry; 1988 Oct; 45(10):929-32. PubMed ID: 3421805
[TBL] [Abstract][Full Text] [Related]
10. Duration of antidepressant trials: clinical and research implications.
Donovan SJ; Quitkin FM; Stewart JW; Ocepek-Welikson K; Harrison W; McGrath PJ; Nunes EV; Wager S; Tricamo E
J Clin Psychopharmacol; 1994 Feb; 14(1):64-6. PubMed ID: 8151005
[TBL] [Abstract][Full Text] [Related]
11. Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo.
Raft D; Davidson J; Wasik J; Mattox A
Neuropsychobiology; 1981; 7(3):122-6. PubMed ID: 7231652
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission.
Stewart JW; Tricamo E; McGrath PJ; Quitkin FM
Am J Psychiatry; 1997 Jan; 154(1):31-6. PubMed ID: 8988955
[TBL] [Abstract][Full Text] [Related]
13. Maintenance phenelzine treatment of major depression: an interim report.
Robinson DS; Kayser A; Bennett B; Devereaux E; Lerfald SC; Albright D; Laux D; Corcella J
Psychopharmacol Bull; 1986; 22(3):553-7. PubMed ID: 3099323
[No Abstract] [Full Text] [Related]
14. An outpatient evaluation of phenelzine and imipramine.
Davidson J; Raft D; Pelton S
J Clin Psychiatry; 1987 Apr; 48(4):143-6. PubMed ID: 3549705
[TBL] [Abstract][Full Text] [Related]
15. A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives.
Rothschild R; Quitkin HM; Quitkin FM; Stewart JW; Ocepek-Welikson K; McGrath PJ; Tricamo E
Int J Eat Disord; 1994 Jan; 15(1):1-9. PubMed ID: 8124322
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant specificity in atypical depression.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison WM; Markowitz JS; Rabkin JG; Tricamo E; Goetz DM; Klein DF
Arch Gen Psychiatry; 1988 Feb; 45(2):129-37. PubMed ID: 3276282
[TBL] [Abstract][Full Text] [Related]
17. Chronic depression: response to placebo, imipramine, and phenelzine.
Stewart JW; McGrath PJ; Quitkin FM; Rabkin JG; Harrison W; Wager S; Nunes E; Ocepek-Welikson K; Tricamo E
J Clin Psychopharmacol; 1993 Dec; 13(6):391-6. PubMed ID: 8120152
[TBL] [Abstract][Full Text] [Related]
18. Response to phenelzine among depressed patients with features of hysteroid dysphoria.
Kayser A; Robinson DS; Nies A; Howard D
Am J Psychiatry; 1985 Apr; 142(4):486-8. PubMed ID: 3883817
[TBL] [Abstract][Full Text] [Related]
19. Phenelzine vs placebo in 50 patients with bulimia.
Walsh BT; Gladis M; Roose SP; Stewart JW; Stetner F; Glassman AH
Arch Gen Psychiatry; 1988 May; 45(5):471-5. PubMed ID: 3282482
[TBL] [Abstract][Full Text] [Related]
20. A comparison of phenelzine and imipramine in depressed inpatients.
Davidson JR; McLeod MN; Turnbull CD; Miller RD
J Clin Psychiatry; 1981 Oct; 42(10):395-7. PubMed ID: 7026542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
